At Caprion-HistoGeneX, our top priority is the health and safety of our employees, our partners and our clients. Just like you, our team follows the COVID-19 pandemic closely to ensure rapid response as the situation evolves. As we remain committed to ensuring our clients and partners can continue moving their research forward, we have taken different steps to mitigate risks and ensure our continued support around the world. Here is some information about these measures:

  • We have implemented an internal policy ensuring that our employees respect all the measures required to minimize the risk of infection and dissemination within our facilities, including social distancing and good hygiene practices, based on WHO and local recommendations
  • All employees who can do so are required to work from home
  • Access to our facilities is restricted to our employees and to suppliers whose services are absolutely required to maintain our activities
  • All non-essential business travels have been cancelled and employees returning from a trip are self-isolating at home
  • Operational teams are split through different workspace or work shifts, whenever possible to reduce risk
  • We are in close communication with our suppliers to ensure a continuous supply of all critical material and reagents.

Our management team meets daily to monitor the situation and adapt our mitigation plan to help “flatten the curve” while reducing disruptions for our clients.

All our laboratories are currently operational, and we remain committed to continuing to support our partners during these critical times and hope you and your loved ones are and will remain safe.

For any questions regarding this particular situation, please contact our This email address is being protected from spambots. You need JavaScript enabled to view it.. All other questions may be directed to This email address is being protected from spambots. You need JavaScript enabled to view it..


Martin LeBlanc
President & CEO
Caprion Biosciences-HistoGeneX

We are pleased to bring this update to you about our Chinese laboratory. Despite the coronavirus outbreak, we are very excited by the progress we are making for this landmark facility and very much appreciate your encouragement, enthusiasm and questions. We will provide these monthly updates as we approach our go-live date of June 2020.


In early November, HistoGeneX pathologists published a paper in Nature Medicine, in collaboration with researchers from Barts Cancer Institute, Queen Mary University of London.


We are delighted to announce that HistoGeneX will start a histopathology biomarker laboratory in China. This update is the first issue of our Chinese journey. We will provide our progress via this communication. Please include us in your global clinical trial planning and send us your questions.